Zymeworks Competitors and Similar CompaniesClear all
Zymeworks's competitors and similar companies include NovoCure, ImmPACT-Bio, Neovii and Eutilex.
 Zymeworks Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. |  NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. |  ImmPACT-Bio ImmPACT-Bio is a company that develops a chimeric antigen receptor T-cell (CAR-T) therapy. |  Neovii Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.
|  Eutilex Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology. | |
Founding Date | Founding Date 2003 | Founding Date 2000 | Founding Date 2017 | Founding Date 2003 | Founding Date 2015 |
Type | Type Public | Type Public | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations Vancouver, CA HQ Seattle, US | Locations Camarillo, US HQ Rishon Le Tsiyon, IL | Locations Rapperswil-Jona, CH HQ Gräfelfing, DE Lexington, US | Locations KR HQ | |
Employees | Employees 45519% increase | Employees 1,16714% increase | Employees 89 | Employees 1001% increase | Employees 101 |
Valuation ($) | Valuation ($) 432.1 m | Valuation ($) 1.8 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A |
Twitter followers | Twitter followers 1.3 k | Twitter followers 2.5 k | Twitter followers N/A | Twitter followers N/A | Twitter followers N/A |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 16 | Number of tweets (last 30 days) 2 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 1.9 | Average likes per tweet (last 30 days) 6.5 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 81.25% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A |
Employee Rating | Employee Rating 2.8 | Employee Rating 3.3 | Employee Rating N/A | Employee Rating N/A | Employee Rating N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $412.5m (FY, 2022) | Revenue (est.) $537.8m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ₩215.7m (FY, 2022) |
Cost of goods | Cost of goods N/A | Cost of goods $104.2m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $412.5m (FY, 2022) | Gross profit $433.6m (FY, 2022) | Gross profit N/A | Gross profit N/A | Gross profit ₩2.8b (FY, 2022) |
Net income | Net income $124.3m (FY, 2022) | Net income ($92.5m) (FY, 2022) | Net income N/A | Net income N/A | Net income (₩34.5b) (FY, 2022) |
Funding | |||||
Total funding raised | Total funding raised $ 125.9m | Total funding raised N/A | Total funding raised $ 18m | Total funding raised N/A | Total funding raised $ 18.9m |
For sources of this data, please see the company profile
View Company Profiles
NovoCure
HQ
Saint Helier, JE
Employees
1,167↑ 14% increase
NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.
View companyImmPACT-Bio
HQ
Camarillo, US
Employees
89
ImmPACT-Bio is a company that develops a chimeric antigen receptor T-cell (CAR-T) therapy.
View companyNeovii
HQ
Rapperswil-Jona, CH
Employees
100↑ 1% increase
Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.
View companyEutilex
HQ
KR
Employees
101
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology.
View company